Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PPIA | P62937 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6063409 | 1.00 | DPP4 (0.35) | DPP4GFERAGTR2KDM4ELMNA | |
| SCHEMBL6479927 | 1.00 | DPP4 (0.35) | DPP4GFERAGTR2KDM4ELMNA | |
| SCHEMBL6062357 | 0.91 | DPP4 (0.36) | DPP4GFERAGTR2KDM4ELMNA | |
| SCHEMBL6062214 | 0.91 | DPP4 (0.38) | DPP4GFERAGTR2KDM4ELMNA | |
| SCHEMBL6063522 | 0.91 | DPP4 (0.36) | DPP4GFERAGTR2KDM4ELMNA | |
| SCHEMBL8294822 | 0.89 | PPIA (0.31) | PPIA | |
| SCHEMBL1728832 | 0.85 | DPP4 (0.35) | DPP4GFERPPIA | |
| SCHEMBL1728385 | 0.85 | DPP4 (0.35) | DPP4GFERPPIA | |
| SCHEMBL1728242 | 0.85 | DPP4 (0.35) | DPP4GFERPPIA | |
| SCHEMBL6479943 | 0.83 | PPIA (0.40) | DPP4GFERAGTR2PPIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059716-A1 | Novel bicyclic cyanoheterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059716-A1 | Novel bicyclic cyanoheterocycles, process for their preparation and their use as medicaments | CYP11B2, GOT2, CYP11B1 | DPP4 374/4885GFER 2016/4885AGTR2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.